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Available online 27 December 2013Abstract The hTERT-immortalization of human bonemarrow-derived Mesenchymal Stromal Cells (hMSCs) was proposed to address
availability/standardization issues for experimental or clinical studies, but raised concerns due to possible uncontrolled growth or
malignant cell transformation.
Here we report a method to generate a hMSCs line with controlled survival, through the implementation of a pre-established
suicide system (inducible caspase 9, iCasp9) in hTERT-transduced hMSCs.
Primary hMSCs were successfully immortalized (N280 PD) and further transduced with the iCasp9 device. A clone was selected
and shown to maintain typical properties of primary hMSCs, including phenotype, differentiation and immunomodulation capacities.
The successive transductions did not induce tumorigenic transformation, as assessed by analysis of cell cycle regulators and in vivo
luciferase-based cell tracking. Cells could be efficiently induced toward apoptosis (N95%) both in vitro and in vivo.
By combining the opposite concepts of ‘induced-life’ and ‘inducible-death’, we generated a hMSCs line with defined properties
and allowing for temporally controlled survival. The cell line represents a relevant tool for medical discovery in regenerative
medicine and a potential means to address availability, standardization and safety requirements in cell & gene therapy. The
concept of a hTERT-iCasp9 combination, here explored in the context of hMSCs, could be extended to other types of
progenitor/stem cells.
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585Generation of hMSCs with controlled survivalIntroductionHuman bone marrow-derived Mesenchymal Stem/Stromal
Cells (hMSCs) are widely investigated in regenerative medicine
due to their multilineage differentiation capacity (Pittenger et
al., 1999), immunomodulatory properties (Nauta and Fibbe,
2007), as well as their ability to migrate and deliver regulatory
factors at injured sites or within tumor stroma (Kidd et al.,
2009). Despite the large scientific interest and broad range of
potential therapeutic applications, the coherent pre-clinical
and clinical use of hMSCs is challenged by several critical issues,
including the limited availability and the variability among
different donors (Phinney et al., 1999).
The low amount of hMSCs in bone marrow aspirates (0.001
to 0.1% of nucleated cells) typically necessitates an in vitro
expansion phase prior to use. The phase of amplification is
limited by the replicative senescence phenomenon occur-
ring under in vitro culture conditions, typically after 30 to
40 population doublings (PD) (Stenderup et al., 2003). Along
with serial passages, the differentiation potential of hMSCs
is reduced and functional changes have been reported
(Minguell et al., 2001; Siddappa et al., 2007). The need
for extensive hMSCs expansion, combined with their short
life-span, is aggravated by the high variability among prepa-
rations from different donors, even if in the same age range
(Siddappa et al., 2007).
To overcome hMSCs standardization and supply based
problems, the generation of immortalized hMSCs was devel-
oped through the insertion of a human telomerase catalytic
subunit (hTERT) (Boker et al., 2008;Huang et al., 2008;Jun
et al., 2004;Piper et al., 2012;Simonsen et al., 2002a). The
generation of hTERT-MSCs lines allowed extended hMSCs
lifespan (N300 PD) and was shown to preserve some of the
properties of primary hMSCs, such as their multilineage
differentiation potential (toward osteogenesis, chondro-
genesis and adipogenesis) (Abdallah et al., 2005; Jun et al.,
2004; Mihara et al., 2003) and bone formation capacity
(Simonsen et al., 2002b).
The enthusiasm raised by the availability of an unlimited
cell source with stabilized properties was however tempe-
red by safety aspects. A strong telomerase expression was
in fact associated with many cancer types (Counter et al.,
1998;Latil et al., 2000), and neoplastic changes have been
reported following hTERT-transformation of hMSCs (Burns et
al., 2005;Serakinci et al., 2004) resulting in uncontrolled cell
growth. Such risk may be aggravated if hMSCs are delivered
within a 3D matrix as opposed to systemic infusion, due to the
previously reported enhanced long-term engraftment (Daga et
al., 2002).
An elegant approach was recently proposed to enhance
the safety of cellular therapies by the use of an inducible
death-system (iDS) (Ramos et al., 2010;Straathof et al.,
2005), based on the expression of a modified caspase 9
(iCasp9).
Beyond safety considerations, the introduction of an iDS
may additionally offer the unprecedented opportunity to
temporally control the survival of the transduced cells, in
order to investigate their functional role in in vitro or in vivo
models. However, while the device demonstrated a great
efficiency in primary cells (Ramos et al., 2010; Straathof et
al., 2005), no study has yet reported its functionality inimmortalized cells. The concept may in fact be challenged
by the fact that a hTERT over-expression has been previously
associated to cell-suicide inhibition (Deeb et al., 2012;
Indran et al., 2011; Liang et al., 2012), conferring notably a
resistance to caspase-mediated apoptosis (Bermudez et al.,
2006).
Toward the standardized, controlled and versatile use
of hMSCs, we then aimed at assessing the feasibility to as-
sociate immortalization and ‘inducible-death’ concepts to
generate a hTERT-hMSCs line efficiently inducible to apo-
ptosis and maintaining the typical properties of primary
hMSCs. The successful hTERT and iDS combination is expec-
ted to lead to the generation of an unlimited and well
characterized hMSCs source with controlled survival, open-




Human bone marrow aspirates were obtained during routine
orthopedic surgical procedures involving exposure of the
iliac crest, after ethical approval (EKBB, Ref.78/07) and
informed donor consent. Marrow aspirates (20 ml volumes)
were harvested from a healthy donor (female, 51 years old)
using a bone marrow biopsy needle inserted through the
cortical bone and immediately transferred into plastic tubes
containing 15,000 IU heparin. After diluting the marrow
aspirates with phosphate buffered saline (PBS) at a ratio of
1:4, nucleated cells were isolated using a density gradient
solution (Histopaque, Sigma Chemical, Buchs, CH). Com-
plete medium consisted of either Dulbecco's modified Eagle
medium (DMEM) or α-minimum essential Medium (αMEM)
with 10% fetal bovine serum, 1% HEPES (1 M), 1% Sodium
pyruvate (100 mM) and 1% of Penicillin–Streptomycin–
Glutamine (100×) solution (all from Gibco). Nucleated cells
were plated at a density of 3.106 cells/cm2 in complete
medium supplemented with 5 ng/ml of fibroblast growth
factor-2 (FGF-2, R&D Systems) and cultured in a humidified
37 °C/5% CO2 incubator. In immortalized cell cultures, FGF-
2 supply was interrupted after 140 PD, due to both the
steady proliferation observed even in its absence and the
possible impairment of the multi-lineage potential of hMSCs
(Lai et al., 2011). Medium was changed twice in a week.
hMSCs were selected on the basis of adhesion and prolifer-
ation on the plastic substrate 1 week after seeding.Cell engineering
Immortalization
Immortalization was performed by the use of a lentivirus
Lenti-hTERT-eGFP (LG508, Biogenova). Infection of hMSCs was
performed 1 week after isolation and plating of the nucleated
cell fraction from bonemarrow aspirate. The virus was delivered
at a Multiplicity Of Infection (MOI) of 5 in complete medium
supplemented with 8 μg/mL of polybrene (Sigma Aldrich).
The MOI was selected following preliminary experiments, in
order to obtain high transduction efficiency while preserving the
586 P. Bourgine et al.cell functionality. The success of immortalization was assessed
by flow cytometry (eGFP expression), telomerase activity
measurement (TraP assay, Millipore, cat# S7700), a senes-
cence assay (β-galactosidase assay, Sigma Aldrich, cat#
CS0030) and by following the population doublings (PD) of
the cells. The formula PD(n/(n − 1)) = (log(Nn/Nn − 1))/log2
was used for the calculations of the PD at passage n, based
on the number N of counted cells. The cumulative popu-
lation doubling levels (PDL) are the sum of population doub-
lings (PD) across each serial passage.
Retrovirus production
The retro-vector carrying the modified caspase 9 and CD19
(iCasp9-ΔCD19) was kindly provided by Dr. Carlos Almeida
Ramos (Baylor College of Medicine, Houston, Texas, USA).
The retrovirus was produced after transfecting the phoenix
ECO cell line (American Type Culture Collection, cat#
SD3444;) with the iCasp9-ΔCD19 vector. Virus containing
supernatant was collected every 12 h, passed through a
0.45 μm filter and conserved at −80 °C.
The MSCV Luciferase PGK-hygro plasmid (Addgene plas-
mid 18782) was used for the production of retrovirus carrying
the luciferase system (retro-Lucif). The virus production was
performed using the same protocol as for the iCasp9-ΔCD19
retrovirus. Cells were selected by hygromycin B (Sigma, cat#
H3274) treatment for 2 weeks.
Retroviral transduction
hMSCs were plated at 6000 cells/cm2 in 60-mm dishes the
day preceding the transduction. Cells were transduced by
incubation with retroviral vector supernatants supplement-
ed with 8 μg/μL of polybrene (Sigma Aldrich) for 5 min at
37 °C and centrifuged at 1100g for 30 min at room temper-
ature in the dishes, followed by fresh medium replacement.
Cell Sorting
hMSCs stably expressing hTERT-eGFP and/or iCasp9-ΔCD19
were purified using a FACS-Vantage SE cell sorter (Becton
Dickinson, Basel, Switzerland). Cells were sorted after
immortalization and iCasp9-ΔCD19 transduction at 30 PDL
and 195 PDL respectively. Prior to sorting of the CD19Figure 1 Generation of hTERT-iDS hMSCs line. A) Functional map
immortalization of primary hMSCs. The system consists in a human t
separated CMV promoters.B) Telomerase activity of primary hMSCs and
(hTERT-MSCs) displayed a higher telomerase activity (N4-fold) tha
telomerase activity of the immortalized population remained stable (r
levels of primary (black stars) and immortalized hMSCs (white dots). Af
M-SOD cells by passed the senescence-associated crisis. After 170 PD, th
population. The M-SOD population underwent more than 270 PD after
hMSCs (35 PD) and hTERT-iDS (50 PD) population. The primary hMSC
reaching 35 PD, indicating an entry in a replicative senescence phase.
crisis and continued to proliferate.E) Functional map of the iCasp9-Δ
caspase 9 (iCaspas9) that can be induced toward dimerization thus lead
between the iCaspase9 and CD19 gene ensures the cleavage of the C
mRNA.F) CD19 expression of the hTERT-iDS cell line. A homogenou
successfully transduced cells, resulting in the isolation of the hTERT
system implemented in the hTERT-iDS population. Prior to apoptosis ac
negative for Annexin-V and PI stainings (left panel). After activation
Dimerization (right panel), more than 99% of the cells were killed (popositive fraction, cells were labeled using a human anti
CD19-PerCP antibody (BD BIOSCIENCES, cat# 561295).
Cell characterization
Cell phenotyping
hMSCs phenotype was determined by cytofluometry analysis
with fluorochrome-conjugated antibodies to human CD44
(cat# 559942), CD29 (cat# 555443), CD73 (cat# 560847),
CD90 (cat# 559869), CD34 (cat# 555822), CD45 (cat# 555483),
CD146 (cat# 550315), CD19 (cat# 561295), Epcam (cat# 347200)
all from BD Pharmingen, and E-cadherin (cat#FAB18381P) from
R&D Systems.
Adipogenic differentiation
hMSCs were differentiated as previously described (Barbero et
al., 2003; Jaiswal et al., 1997; Jakob et al., 2001). Briefly, cells
were seeded at 3000 cells/cm2 and cultured for 1 week in
DMEM complete medium without passage. During the follo-
wing 2 weeks, cells were exposed to four differentiation cycles
consisting in alternating ‘strong’ adipogenic medium (Dexa-
methasone 10−6 M, Indomethacin, Insulin, IBMX) for 3 days and
‘light’ adipogenic medium (Insulin) for 1 day.
Osteogenic differentiation
hMSCs were seeded at 3000 cells/cm2 and differentiated
for 3 weeks in osteogenic medium (OM). Osteogenic me-
dium consists in αMEM complete medium supplemented with
10 nM Dexamethasone, 0.1 mM L-ascorbic acid-2-phosphate
and 10 mM β-glycerophosphate (Maniatopoulos et al., 1988).
Chondrogenic differentiation
Culture of hMSCs was performed in 0.5 ml of DMEM containing
4.5 mg/ml D-Glucose, 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate, 100 mM HEPES buffer, 100 U/ml penicillin,
100 mg/ml streptomycin, and 0.29 mg/ml L-glutamine supple-
mented with 0.1 mM ascorbic acid 2-phosphate, 10 ng/ml TGFb1
and 10−7 M dexamethasone (Chondrogenic medium) as previ-
ously described (Jakob et al., 2001). Cells (350,000) were
centrifuged in 1.5 ml conical polypropylene tubes (Sarstedt,
Numbrecht, Germany) to form spherical pellets. After 2 weeksof the lenti-hTERT-eGFP (Biogenova, LG508) vector use for the
elomerase gene and a eGFP reporter gene, under the control of
the immortalized population (Trap assay). The immortalized cells
n their primary counterpart. Despite extensive doublings, the
espectively assessed at 50, 100 and 150 PD).C) Population doubling
ter 35 doublings, the primary cells stopped to proliferate while the
e inducible death system (iDS) was introduced in the immortalized
more than one year of culture.D) β-galactosidase assay of primary
s were shown to degrade β-galactosidase (blue coloration) when
The immortalized population bypassed the senescence-associated
CD19 retrovector. The device drives the expression of a modified
ing to the activation of the apoptotic pathway. A 2A-like sequence
D19 surface marker from the iCaspase9, after transduction of the
s population (N98%) could be sorted after CD19 labeling of the
-iDS population.G) Functional assessment of the inducible death
tivation, the majority (N93.6%) of the population was shown to be
of the system by an overnight exposure to the Chemical Inducer
sitivity for Annexin-V or PI).
587Generation of hMSCs with controlled survivalof culture, pellets were processed for histology and gene
expression analysis.
Real-time PCR
Total RNA was extracted from cells using TRIzol (Invitrogen,
Carlsbad, CA), treated with DNAse and retrotranscribed into
DNA, as previously described (Frank et al., 2002). Real-timePCR was performed with the ABIPrism 77000 Sequence
Detection System (Perkin Elmer/Applied Biosystem, Rotkreuz,
Switzerland) and expression levels of genes of interest were
normalized to GAPDH. Primers and probe sets of chondrogenic
and osteogenic genes were used as previously described (Frank
et al., 2002). Human PPARγ (Hs00234592_m1) Retinoblastoma
1, p53 (Hs01034249), p21 (Hs00355782_m1) primers and probe
Table 1 Cytofluorimetric analysis of the primary cells and the generated cell line at different development time. The generated cell lines stably expressed conventional markers for
hMSCs (CD44, CD29, CD73, CD90) while being negative for hematopoietic (CD34, CD45) and epithelial markers (Epcam, E-cadherin). The eGFP and CD19 expression respectively reflects
the successful immortalization and iDS insertion. The successive genetic transformations and extensive doublings did not impair the mesenchymal phenotype of the cells.
+ + + + + +
+ + + + + +
+ + + + + +
+
+
+ + + + +
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Figure 2 Osteogenic differentiation and killing assessment of M-SOD. A) Alizarin red staining of M-SOD cells after 3 weeks of culture
in complete (CM) or osteogenic medium (OM). Only in presence of osteogenic medium, cells were able to deposit a mineralized matrix
(red nodules). Size bar = 1 cm. B) Gene expression levels of key osteoblastic genes after 14 days of culture in osteogenic medium. As
compared to cells assessed prior to culture in OM (expanded cells), a significant upregulation of Alkaline Phosphatase (ALP), Bone
Morphogenetic Protein 2 (BMP-2), Bone Sialoprotein, Osteocalcin (OC) and RunX2 (Run-related transcription factor 2) was observed.
*, p b 0.05. C) Induction of death during osteogenic differentiation of the SOD cell line. Cells were induced toward death (+CID) after
1, 2, or 3 weeks of culture in osteogenic medium (OM). Following exposure to CID, more than 95% of the cells became Annexin-V or PI
positive, independently of their differentiation state. ***, p b 0.001.
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Alizarin red, oil red-O and Alcian blue biochemical stainings
were used to respectively assess the osteogenic, adipogenic andchondrogenic differentiation of the cells, as previously de-
scribed (Barbero et al., 2003;Jaiswal et al., 1997;Jakob et al.,
2001).
Karyotypic analysis
The karyotype of the M-SOD line was investigated by
G-banding analysis. Briefly, cells in metaphase were fixed
using fresh stationary liquid (methanol:glacial acetic acid =
3:1), spread on slides, stained with Giemsa solution, and
observed under an immersion objective. n = 4.
591Generation of hMSCs with controlled survivalDNA profiling
The DNA profile of the primary hMSCs, the hTERT-hMSCs and
of the M-SOD line was assessed by comparison of 15 DNA
features inherited independently of each other, namely the
following Short Tandem Repeats (STRs): D3S1358, THO1,
D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539,
CSF1PO, Penta D, vWA, D8S1179, TPOX, FGA. The samples
were analyzed by VIOLLIER AG (Basel, Switzerland).Tumorigenicity assay
One million M-SOD cells previously transduced with the
retro-Lucif virus were mixed with Matrigel Matrix (BD Biosci-
ences) in a ratio 1:1 (V/V) with PBS and injected subcutane-
ously into the left flank of NOD/SCID mice (8–10 weeks
old mice), initially obtained by Charles River Laboratories
(Germany). Eventual tumor growthwasmonitored both weekly
by palpation and by in vivo luminescence signal acquisition
using an ISIS luminometer system. Prior to acquisition, mice
received an intraperitoneal injection of 300 μL of D-Luciferin
Potassium salt (Goldbiotechnology) at 15 mg/mL. Cells were
tracked for a period of 6 months post-injection.In vivo bone formation
In vivo ectopic bone formation was assessed as previously
described (Braccini et al., 2005). Briefly, cells were resus-
pended in 30 μl of Fibrinogen (20 mg/ml Baxter, Austria),
mixed with 30 μl of Thrombin (6 IU/ml Baxter, Austria) and
immediately loaded onto 35 μg of bovine bone-derived
granules (Actifuse, Apatech, Baxter, Austria). The constructs
were transferred for 15 min in a humidified incubator at 37 °C
with 5% CO2 to allow fibrin polymerization and implanted
subcutaneously in CD-1 nu/nu nude mice (Charles River,
Germany). After 8 weeks, the constructs were harvested,
fixed overnight in 4% formalin, decalcified with a decal-
cification solution made of 7% EDTA (Sigma, cat# E5134)
and 10% sucrose (Sigma, cat# S9378), paraffin embedded and
5 μm-thick-sections were obtained from different levels.
Sections were stained with Masson's trichrome and observed
microscopically to detect histological features of bone tissue.
For fluorescence analysis, samples were fixed in 1.5% para-
formaldehyde, decalcified with 7% EDTA (Sigma, cat# E5134),
embedded in optimal cutting temperature, and snap frozen in
liquid nitrogen. Sections (5 μm thick) were incubated with
DAPI to stain nuclei. Fluorescence images were acquired using
an Olympus BX-61 confocal microscope.Figure 3 Adipogenic/chondrogenic differentiation and killing asse
culture in complete (CM) or adipogenic medium (AM). In presence
differentiated into adipocytes as demonstrated by the positive staini
level after 3 weeks of culture in complete or adipogenic medium.
mRNA level was detected (16.2 fold), thus confirming the capacity o
of death during adipogenic differentiation of the M-SOD cell line. C
3 weeks of differentiation (N95%) in adipogenic medium (AM). A high
of the cells. ***, p b 0.001.D) Alcian blue staining of M-SOD pellets aft
(ChM). Both culture conditions did not lead to the generation of a
Collagen type II (Coll II) and type X (Coll 10) gene expression levels of
in chondrogenic medium (ChM). In chondrogenic conditions, only a
ns = non-significant. *, p b 0.05.Immunomodulation assay (CFSE)
The immunomodulation of hMSCs was assessed as previously
described (Gattinoni et al., 2011). Briefly, hMSCs were
seeded in 96-well plates at 20.000, 10.000, 5000 and 2000
cells/well. CD4+ lymphocytes were extracted from whole
blood PBMCs by magnetic beads labeling (Miltenyi Biotec)
and seeded on top of hMSCs at 1*10^5 cells per well after
labeling with 2 μM CFSE (7 min at 37 °C). The CD4+ cells
were left untreated or stimulated with 1 μg/mL of phytohe-
magglutinin and the proliferation index was determined
after 4 days by flow cytometry and analyzed with FlowJo
software (Treestar).
Death induction
To induce cell death in vitro, the B/B homodimerizer
(Clontech, cat# 635060) was added at 50 nM to iCasp9-ΔCD19
transduced hMSCs in culture medium to activate the apoptosis
pathway through the dimerization of the modified caspase 9.
Percentage of induced death was assessed 12 h later by FACS
analysis, after cell harvest and staining with Annexin V-APC
(BD Biosciences, cat#550475) and Propidium Iodide (PI, BD
Biosciences, cat# 51-66211E) in Annexin-V binding buffer (BD
Biosciences, cat# 556454). Control cells were cultured in the
same medium without exposure to the homodimerizer.
The in vivo killing efficiency of the M-SOD line was assessed
using 0.5 M cells previously transduced with the retro-Lucif
virus, mixed with Matrigel Matrix (BD Biosciences) in a ratio 1:1
(V/V) with PBS and injected subcutaneously into the left flank
of NOD/SCID mice (8–10 weeks old mice, Charles River
Laboratories-Germany). To induce cell-death, mice (group 2,
+CID) received the following day an injection of 50 μg of B/B
homodimerizer (Clontech, cat# 635058) previously diluted in
Tween 2% (SIGMA-ALDRICH, cat# P1379) and Kollisolv® PEG E
400 (SIGMA-ALDRICH, cat# 06855) according to the manufac-
turer instructions. The control group (group 1, no CID) consisted
in mice receiving injection of diluent (Tween 2% and Kollisolv®
PEG E 400) without B/B homodimerizer. The success of
apoptotic induction was assessed by in vivo luminescence
signal acquisition using an ISIS luminometer system. Prior to
acquisition, mice received an intraperitoneal injection of
300 μL of D-Luciferin Potassium salt (Goldbiotechnology) at
15 mg/mL. The luminescence signal emitted by cells was
measured up to 4 days post-killing induction.
Statistical analysis
Data are presented as means ± standard error. The sig-
nificance of differences was evaluated using analysis ofssment of M-SOD.A) Oil red-O staining of M-SOD after 3 weeks of
of adipogenic medium, the M-SOD cell line was successfully
ng of lipid droplets. Size bar = 200 μm.B) PPARγ gene expression
In adipogenic conditions, a significant overexpression of PPARγ
f M-SOD to differentiate into adipocytes. *, p b 0.05.C) Induction
ells were efficiently induced toward death (+CID) after 1, 2 or
killing efficiency (N95%) was reached despite the differentiation
er 2 weeks of culture in complete (CM) or chondrogenic medium
rich cartilaginous matrix (blue staining). Size bar = 100 μm.E)
M-SOD cells before (expanded) or after 2 weeks of pellet culture
significant overexpression of Coll 10 mRNA level was observed.
592 P. Bourgine et al.variance (ANOVA) followed by the Bonferroni test for every
set of data on which multiple comparisons were performed.
For single comparison, Mann–Whitney test was used. p b0.05
was considered to indicate statistical significance.
Results
Immortalization of human bone marrow derived
mesenchymal stromal cells
Primary hMSCs were transduced with a lentivirus carrying the
human telomerase gene (Fig. 1A). The rate of transduction
was assessed by flow cytometry through the enhanced GFP
(eGFP) reporter gene. After transduction, 78% of the cell
population expressed the transgene. The eGFP positive
fraction was sorted to increase the purity of the transduced
population (Supp. data 1). The functionality of the imple-
mented human telomerase gene was assessed by telomeric
repeat amplification protocol (TRAP), allowing for a sensitive
measurement of the telomerase activity. The immortalized
population (hTERT-hMSCs) stably displayed higher telomerase
activity (4.4 ± 1.5 fold) than their primary counterpart (prima-
ry hMSCs), even after extensive proliferation (shown up to 150
doublings, Fig. 1B). Primary hMSCs did not proliferate for more
than 35 PD, while the immortalized hMSCs underwent more
than 270 PD (Fig. 1C). Primary cells became senescent after 35
PD as assessed by β-galactosidase staining, while the trans-
duced population bypassed the senescence associated crisis
(Fig. 1D). The clonogenicity of the immortalized population was
about 8-fold higher than for primary hMSCs (9.3% vs 80.3%). A
stable hTERT-hMSCs line with steady proliferation capacity was
thus successfully generated.
Generation of a clonal hTERT-iDS hMSCs line
After 170 PD, the hTERT-hMSCs line was transduced with the
retrovirus carrying an inducible death system (iDS), including
CD19 as reporter gene (Fig. 1E). After one round of trans-
duction, more than 50% of the cells expressed CD19. After
sorting, more than 98% of the cells expressed the reporter gene
(Fig. 1F), resulting in the isolation of a stable hMSCs line
uniformly carrying the death-inducible system (hTERT-iDS).
The functionality of the iDS was investigated by exposing the
hTERT-iDS line to the Chemical Inducer of Dimerization (CID),
leading to the activation of the suicide system. Following
overnight exposure to CID (Fig. 1G and supplemental online
video 1), more than 99% of the cells were pushed toward death
(PI-positive or Annexin-V-positive). No toxicity was induced by
exposing primary hMSCs or hTERT-hMSCs to CID. An immortal-
ized and death-inducible hMSCs line was thus successfully
generated, demonstrating the possibility to combine a hTERT
overexpression with an efficient iDS-mediated killing.
The immortalization process, combinedwith the insertion of
the iDS and the extensive number of PD, gave rise to a likely
heterogeneous cell line. In order to obtain a more uniform
population, thirty single colonies were picked and 24 of those
could be successfully expanded. We then arbitrarily decided to
select the clone with the most prominent osteogenic differen-
tiation capacity, as this is considered the common, default
differentiation pathway for hMSCs (Muraglia et al., 2000).
Following culture for 3 weeks in osteogenic differentiationmedium, the clone displaying the strongest intensity of alizarin
red staining was selected (Supp. data 2). The immortalized
hMSC clone carrying the iDS was then denominated as the
Mesenchymal-Sword Of Damocles (M-SOD) cell line for
further characterization.
Purity assessment and phenotypic analysis of primary
hMSCs and the generated cell line(s)
The phenotype of the cell line was cytofluorimetrically
assessed at different doublings and after each genetic modi-
fication (Table 1). All transformed cells expressed typical
hMSCs markers (positivity for CD44, CD29, CD73, and CD90)
while being negative for both the hematopoieticmarkers CD34
and CD45 and the epithelial markers EpCam and E-cadherin.
The immortalized population was also shown to increasingly
express the CD146 marker following FGF-2 removal from the
supplemented medium (at 140 PD), consistently with a
previous study (Sacchetti et al., 2007). The successive genetic
modifications and extensive proliferation of the cell line were
thus shown to not lead to an alteration of the mesenchymal
phenotype, as assessed by conventional markers.
In addition, despite extensive in vitro culture time the
DNA profile of the primary hMSCs, hTERT-hMSCs and M-SOD
remains identical, as demonstrated by STRs analysis (Supp.
data 3). This demonstrates the absence of potential contam-
inations by other cell sources. Moreover, a karyotypic analysis
of the M-SOD line revealed that M-SOD cells displayed the
same chromosomal pattern, thus demonstrating the homoge-
neity of the generated cell line (data not shown).
Differentiation capacity of M-SOD line
Themultilineage differentiation capacity of the M-SOD line was
tested after different numbers of population doublings (ranging
from 250 PD to over 280PD) in order to investigate the stability
of M-SOD properties. Data presented below are the average of 4
different experimental runs.
After 3 weeks of culture in osteogenic medium (OM), M-SOD
cells deposited a thick mineralized matrix, as demonstrated by
positive alizarin red staining (Fig. 2A). A strong induction of key
osteogenic genes (Fig. 2B) was detected after 2 weeks of
culture in osteogenic conditions (94.8-, 8.5-, 130.9-, 16.1- and
58.7-fold for ALP, BMP-2, BSP, OC and RunX2 genes respective-
ly, p b 0.05). The M-SOD line was thereby shown to be capable
to efficiently differentiate toward the osteogenic lineage.
After 3 weeks of culture in adipogenic medium, M-SOD
cells were successfully differentiated into adipocytes, as
revealed by the positive Oil red-O staining of the lipid
droplets (Fig. 3A). The upregulation of the adipogenic PPARγ
gene (16.2-fold, Fig. 3B, p b 0.05) confirmed the capacity of
the M-SOD line to differentiate toward the adipogenic
lineage.
The chondrogenic differentiation capacity of the M-SOD
line was assessed by Alcian blue staining after pellet culture
in complete or chondrogenic medium (Fig. 3D). M-SOD cells
did not generate a GAG-rich cartilaginous matrix and did not
significantly upregulate Sox-9 (data not shown) or type II
Collagen, despite a marked increase in type X Collagen gene
expression level (291-fold, Fig. 3E, p b 0.05). Nevertheless,
the primary donor fromwhom theM-SOD linewas derivedwas also
Figure 4 Bone formation and immunomodulatory capacities of M-SOD. A) In vivo bone formation of the M-SOD cell line. Cells
successfully formed bone nodules (B) in contact with the ceramic granules (Ce), as demonstrated by Masson's trichrome staining (up)
8 weeks post in vivo implantation. Size bar = 50 μm and 1 mm for the lower magnification inset. B) Fluorescence microscopic analysis
of bone formation of the M-SOD line. The eGFP signal (green) surrounding the bone nodules (B) demonstrates the contribution of
M-SOD cells to the formed bone. Size bar = 50 μm. The blue signal refers to cell nuclei staining (DAPI). C) Immunomodulation assay
(CFSE) of the M-SOD line. The percentage of proliferating CD4+ after 4 days of culture, with different ratios of M-SOD cells, +/− PHA
activation. D) Peaks of fluorescence in the activated CD4+, alone or in co-culture (1:5) with M-SOD cells, 4 days post PHA activation. In
the absence of M-SOD, 5 peaks of fluorescence were observed corresponding to 4 division cycles.
593Generation of hMSCs with controlled survivalnot capable to differentiate toward the chondrogenic lineage
(Supp. data 4). This suggests that M-SOD low chondrogenic
capacity may not be due to the successive genetic modifica-
tions or the extensive doublings.Death induction upon osteogenic and adipogenic
differentiation
The chromatin remodeling that occurs during cell differen-
tiation (Benayahu et al., 2007;Siddiqi et al., 2010) can
potentially lead to the silencing of the implemented iDS.
Consequently, the functionality of the iDS system had to be
demonstrated also during cell differentiation.
The death induction efficiency of the M-SOD line was
tested during osteogenic or adipogenic differentiation,
using cells expanded for different numbers of populationdoublings (ranging from 250 to over 280). Data presented
below are the average of 3 different experimental runs.
During osteogenic differentiation, cells were induced with
CID after 1, 2 or 3 weeks of culture in osteogenic medium.
After an overnight exposure to CID, a very high killing efficiency
was reached (97.7 ± 2.1%, Fig. 2C, p b 0.0001) irrespective of
the cell differentiation stage. Similar results were obtained by
inducing M-SOD cells during adipogenic differentiation (97.1 ±
2.5%, Fig. 3C, p b 0.0001). The iDS implemented within the
M-SOD cell line thus remained highly efficient independently of
the differentiation status.
Bone formation capacity of the M-SOD line
The bone formation capacity was assessed by combining
1 million of M-SOD cells together with ceramic granules, in a
fibrinogen/thrombin gel, followed by ectopic implantation in
594 P. Bourgine et al.nude mice (n = 3) for 8 weeks. Samples were retrieved, fixed
and decalcified prior to sectioning and histological analysis.
The cells secreted a dense collagen matrix and the formation
of bone nodules was observed within the constructs, as
demonstrated by Masson's trichrome staining (Fig. 4A). GFP
positive cells were observed at the outer regions of those
nodules, indicating their contribution in the deposition of the
osteoid tissue (Fig. 4B).Figure 5 Assessment of M-SOD safety features. A) Gene expression
The primary hMSCs and M-SOD expressed similar levels of p53,
Tumorigenicity assay of the M-SOD cell line. One million of M-SOD
NOD/SCID mice (n = 3). Two days post cell injection, the luciferase sy
strength of the signal significantly decreased and was undetectab
remained undetectable so far demonstrating their non-tumorigenici
M-SOD cells expressing luciferase were injected into the right fla
injected with 50 μg of CID (group 2, +CID) or only with the diluent (
only in mice having received the apoptotic inducer (+CID), thus dem
in vivo. The figures are representatives of n = 3 independent experiImmunomodulation capacity
hMSCs are known to exhibit immunomodulatory properties,
which include the regulation of T-cell proliferation. This intrinsic
hMSCs capacity has been proposed to be critical toward hMSCs
application for graft versus-host or autoimmune diseases.
To assess whether the M-SOD line could regulate acti-
vated lymphocyte proliferation, CD4+ cells were labeledlevels of key oncogenes in expanded primary hMSCs and M-SOD.
p21, Rb1 and c-Myc. *, p b 0.05. f.d. = fold difference. B)
cells expressing luciferase were injected into the right flank of
stem allows the localization of the M-SOD cells. After 8 days, the
le at day 16. More than 180 days post-injection, M-SOD cells
ty. C) In vivo killing efficiency of the M-SOD line. Half million of
nk of NOD/SCID mice. One day post cell injection, mice were
group 1, no CID). After 7 h, the luminescent signal disappeared
onstrating the possibility to specifically induce M-SOD apoptosis
mental runs using different mice.
Figure 6 Schematic representations of the potential applications of the M-SOD line (see text for more extensive description).
595Generation of hMSCs with controlled survivalwith CFSE and co-cultured with M-SOD cells at different
ratios. The proliferation of CD4+ cells was measured 4 days
post activation with phytohemagglutinin (PHA), by flow
cytometry (Fig. 4C). In the absence of PHA, CD4+ cells did
not proliferate, independently of the presence or not of
M-SOD cells, implying that M-SOD cells alone did not trigger
an immune reaction. In the presence of PHA but in the
absence of M-SOD, CD4+ got activated and strongly prolifer-
ated (N80%), as shown by the 5 peaks of fluorescence
observed, corresponding to 4 division cycles (Fig. 4D). M-SOD
cells were able to inhibit such proliferation in a dose
dependent manner (Fig. 4C). In particular, a 1:5 CD4+/
M-SOD ratio resulted in only one division of CD4+ cells
(Fig. 4D). The M-SOD cell line thus displayed antiprolifera-
tive properties on activated CD4+ lymphocytes. In this
regard, although further in vivo studies would be required
to fully assess the regulatory properties, to the best of our
knowledge the M-SOD line is the first reported bone-marrow
derived hMSCs line capable of immunomodulation.Oncogenes expression level. Tumorigenicity and in
vivo killing assessment of M-SOD
Cell immortalization, as any genetic modification, can result
in a malignant transformation by impairing the cell cycle
regulation. Key proteins, such as p53, p21, retinoblastoma-1
or c-Myc, are known to play an important role as cell cycle
regulators, keeping cell proliferation and DNA replication
under control (Sharpless and Depinho, 2004). The genes p53,p21, retinoblastoma-1 (Rb-1) and c-Myc were expressed to a
similar extent in M-SOD and the primary hMSCs (Fig. 5A), as
shown by the limited fold differences (2.0 ± 0.4, 3.3 ± 3.1,
1.3 ± 0.2 and 2.5 ± 0.6 fold for p53, p21, Rb-1 and c-Myc
respectively). The M-SOD cell line thus keeps expressing
normal levels of cell cycle regulator genes.
The tumorigenicity of the M-SOD cell line was then
investigated in vivo by subcutaneous injection in the flank of
NOD/SCID mice of one million M-SOD cells, previously trans-
duced with a luciferase reporter system (retro-Lucif). Within
few days, the luminescence intensity remained focalized and
rapidly decreased, suggesting the non-proliferation or dissem-
ination of M-SOD cells (Fig. 5B). After more than 180 days
post-injection, neither luminescence nor tumor formation was
detected, indicating the non-tumorigenicity of M-SOD cells in
vivo.
The iDS implemented into the M-SOD line also offers the
possibility to control the survival of the cells in vivo. The in
vivo killing efficiency was investigated by subcutaneously
injecting the M-SOD cells previously transduced with a
luciferase reporter system (retro-Lucif), in the flank of
NOD/SCID mice. The implanted cells were induced toward
apoptosis by intraperitoneal injection of CID. Seven hours
post-killing induction, the M-SOD cells were shown to be
successfully killed as reported by the loss of luminescent
signal (Fig. 5C). Conversely, M-SOD cells transplanted in
mice that did not receive a CID injection kept emitting
a strong signal. The possibility to induce efficiently the
killing of M-SOD cells in vivo was thus successfully
demonstrated.
596 P. Bourgine et al.DiscussionBy combining two typically opposing concepts, namely
immortalization and death-induction, we generated a
hMSCs line with standardized properties and temporal
control over survival. In particular, the M-SOD line was
shown to: a) steadily proliferate, b) differentiate toward the
osteogenic and adipogenic lineages, c) maintain the in vivo
bone forming capacity, d) regulate the proliferation of
activated lymphocytes and e) be efficiently inducible toward
death using a clinically approved compound (Ramos et al.,
2010).
This study demonstrates the feasibility to induce an
optimal killing of hMSCs despite their previous immortaliza-
tion. The finding is not obvious, since the hTERT expression
was previously shown to reduce the activation of caspases 3,
8, and 9, and of pro-apoptotic mitochondrial proteins, while
increasing the expression of the anti-apoptotic mitochondrial
protein Bcl-2 (Deeb et al., 2012; Indran et al., 2011; Liang
et al., 2012). The constitutive expression of the inducible
caspase 9 combined with its downstream role in the apoptotic
pathway, allowed to bypass the hTERT-associated resistance
to apoptosis (Deeb et al., 2012; Indran et al., 2011; Liang et
al., 2012), ensuring a control over the cell survival in both
un-differentiated and differentiated states.
The M-SOD properties appeared to derive from the
primary cells. In fact, the strong osteogenic potency and
limited chondrogenic potential could be related to the
selection of the M-SOD clone as the one with the highest
osteogenic differentiation capacity and to the poor chon-
drogenic ability of the primary hMSCs. Further studies are
needed to confirm that the use of a primary donor or of a
clone with a higher chondrogenic capacity would lead to the
generation of a line capable to more efficiently undergo
chondrogenesis.
The use of immortalized hMSCs with stabilized properties
offers standardization opportunity for research purposes.
This is in contrast to primary hMSCs, which after extensive in
vitro culture undergo senescence or possibly degenerate
into malignant cells (Ben-David et al., 2011;Stenderup et
al., 2003; Tarte et al., 2010). The disposal of an unlimited
cell source also allows a clonal screening and extensive
characterization, as well as the long-term monitoring of the
population. This might be particularly of interest when
introducing further genetic modifications, allowing a full
characterization from the integration site to the stability
and expression level of the transgene.
Despite the random virus-derived integrations, known to
potentially lead to malignant transformations (Du et al.,
2005;Nienhuis et al., 2006), the M-SOD was demonstrated to
be non-tumorigenic, both by assessment of the expression
levels of cell proliferation and DNA replication gatekeepers,
as well as by a standard in vivo test. The method can also be
further optimized by combining hTERT and the iDS in a
same lentivector, under the control of a unique promoter.
Eventually, placing the hTERT gene behind the iDS at the 3′
end can ensure the systematic hTERT silencing in case of
chromatin remodeling (through either a silencing in 5′ of the
promoter or the direct silencing of hTERT in 3′). This
principle would reduce the number of transductions and
guarantee an intrinsic control of successfully immortalizedcells by the iDS. Taken together, the non-tumorigenic
engineering of M-SOD cells, combined with the control
ensured by the iDS, supports the relevance of the developed
strategy as a first step in the perspective of a clinical use. In
this regard, safety concerns would anyway require to be
more comprehensively addressed by a panel of additional
methods (e.g. micro-array analysis), in order to propose the
iDS-hTERT strategy for clinical purposes.
The diversity of hMSCs applications in regenerative
medicine makes the M-SOD line an attractive experimental
tool for a variety of contexts (Fig. 6). Beyond representing a
standard and stable hMSCs source, the iDS activation could
serve for the selective and temporally controlled cell
elimination. This would be relevant in in vitro models, e.g.
to study stage-specific cell–cell conditioning in co-culture
systems, or in in vivo models, e.g. to address the question of
how long the living hMSCs fraction is required in order to
induce specific regenerative/tumor targeting effects or to
be effective in the treatment of immune-related disorders.
The M-SOD line can also be seen as a cellular platform that
can undergo additional genetic modifications to overexpress
defined factors and thus acting as drug carrier. This could be
especially relevant to study the treatment of cancer,
inflammatory or autoimmune diseases through the secretion
of e.g. TRAIL or IFN-γ (Dai et al., 2011;Yang et al., 2009).
In this regard, the demonstrated functionality of the iDS in
vivo offers the possibility to switch off the expression of
implemented transgenes and thus to temporally control
the factor delivery. However, a stringent and quantitative
assessment of the in vivo killing efficiency would require
further transformation of the M-SOD line to express a gene
allowing for their sensitive, non-invasive in vivo tracking
(e.g., production of species-mismatched erythropoietin
(Daga et al., 2002)).
Finally, the M-SOD line represents a unique tool to
engineer devitalized cell-laid matrices with the capacity to
induce or regulate regenerative processes, e.g. to promote
bone formation (Sadr et al., 2012). The M-SOD line would
address standardization issues but also allow the devitaliza-
tion of the engineered matrices upon iDS activation, prior to
off-the-shelf storage. As compared to existing devitalization
methods (e.g., Freeze & thaw cycles or the use of
detergents), the iDS would better preserve the matrix
integrity while leading to an efficient killing of the cells in
a streamlined manufacturing process.ConclusionsThe present study proposes and validates the concept of the
first death-inducible cell line. Although the findings have
been generated in the specific context of hMSCs, the
paradigm can be extended to other cell types for distinct
scientific and/or therapeutic applications. The work repre-
sents the basis toward the general perspective of using
genetic tools not only to modify or understand cellular
function, but also to standardize and increase the safety of
cell-based therapies.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.12.006.
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